Oxipit, UAB

Oxipit, UAB, based in Lithuania, leverages artificial intelligence to enhance medical imaging, particularly through its innovative solutions that assist radiologists in diagnostics and reporting, improving healthcare efficiency and patient outcomes. Founded in 2017, Oxipit is dedicated to advancing medical imaging technology. In March 2026, Sectra AB agreed to acquire Oxipit, UAB from Taiwania Capital, Practica Capital, and Coinvest Capital. The firm is headquartered in Vilnius, Lithuania.

Key founders include Darius Barušauskas and Gediminas Peksys, with Peksys currently serving as CEO. Oxipit has executed 2 deals to date. Oxipit focuses on revolutionizing medical imaging through its advanced AI-driven products, primarily the ChestEye and ChestLink solutions. ChestEye, released in 2019, received CE certification and enables radiologists to generate preliminary reports for 75 chest X-ray findings.

In 2022, Oxipit launched ChestLink, which is recognized as the world's first CE Class IIb-certified autonomous AI imaging application, achieving a remarkable 99. 9% sensitivity in identifying normal chest X-ray studies. These products are designed to address the pressing global shortage of radiologists by automating routine case evaluations, allowing radiologists to concentrate on more complex and high-priority cases. Oxipit primarily serves healthcare providers, including hospitals and radiology clinics, across various geographical markets including Europe, North America, and parts of Asia, enhancing diagnostic accuracy and improving patient care in these regions.

In 2023, Oxipit reported revenue of EUR 17,872. 50 from its structured transactions model, which likely involves subscriptions and direct partnerships with healthcare organizations. Clients, such as hospitals and diagnostic centers, subscribe to Oxipit’s services, gaining access to AI-powered diagnostic tools for a recurring fee. This approach facilitates the integration of the ChestEye and ChestLink products into healthcare workflows.

Oxipit's revenue model supports ongoing collaborations with healthcare providers, ensuring they receive regular updates and enhancements to their AI solutions. The March 2026 acquisition enables Sectra AB to utilize its global footprint, clinical partnerships, and deep integration into radiology workflows to scale Oxipit, UAB’s clinically validated autonomous artificial intelligence solutions to more markets.